Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab in Advanced Non-Adenocarcinoma NSCLC
NCT00596830Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2008
- Primary completion
- Mar 2011
- Countries
- 26
01
Overview
A Phase 3 trial of figitumumab in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Apr 2008; status: terminated.
02
Drugs
figitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00596830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00596830.